Image_4_Reciprocal Relationship Between HDAC2 and P-Glycoprotein/MRP-1 and Their Role in Steroid Resistance in Childhood Nephrotic Syndrome.tif by Harshit Singh (6724346)

“…Compared to baseline, TSA treatment increased mRNA levels of P-gp and MRP-1 (fold change 7.51, 7.31, ^*p < 0.0001 in SRNS) and (fold change 3.49, 3.35, ^*p < 0.0001 in SSNS), respectively. It significantly decreased the level of HDAC2 (fold change 1.50, ^*p < 0.0001 in SRNS) (fold change 2.53, ^*p < 0.0001 in SSNS) patients.…”

Image_3_Reciprocal Relationship Between HDAC2 and P-Glycoprotein/MRP-1 and Their Role in Steroid Resistance in Childhood Nephrotic Syndrome.tif by Harshit Singh (6724346)

“…Compared to baseline, TSA treatment increased mRNA levels of P-gp and MRP-1 (fold change 7.51, 7.31, ^*p < 0.0001 in SRNS) and (fold change 3.49, 3.35, ^*p < 0.0001 in SSNS), respectively. It significantly decreased the level of HDAC2 (fold change 1.50, ^*p < 0.0001 in SRNS) (fold change 2.53, ^*p < 0.0001 in SSNS) patients.…”

Image_1_Reciprocal Relationship Between HDAC2 and P-Glycoprotein/MRP-1 and Their Role in Steroid Resistance in Childhood Nephrotic Syndrome.tif by Harshit Singh (6724346)

“…Compared to baseline, TSA treatment increased mRNA levels of P-gp and MRP-1 (fold change 7.51, 7.31, ^*p < 0.0001 in SRNS) and (fold change 3.49, 3.35, ^*p < 0.0001 in SSNS), respectively. It significantly decreased the level of HDAC2 (fold change 1.50, ^*p < 0.0001 in SRNS) (fold change 2.53, ^*p < 0.0001 in SSNS) patients.…”

<i>Theileria annulata</i> parasites with M128I mutation in cytochrome B (<i>Ta</i>M128I) resist buparvaquone treatment. by Shahin Tajeri (3609266)

“…A clear right shift in dose-response curve resulted from decreased susceptibility of macrophages transformed by <i>Ta</i>M128I parasite compared to the wild type is detectable. …”

Increased aggregation propensity enhances Pept-in antimicrobial potency by promoting Pept-in accumulation and IB formation. by Guiqin Wu (760045)

“…This figure is associated with data from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0283674#pone.0283674.s009" target="_blank">S3 Table</a>. …”

Table_1_Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease.docx by Ruixin Song (15399459)

“…Within 30 days of booster immunization, the positive rates of nCoV NTAb and nCoV S-RBD in patients with CLD rapidly increased from 29.0% and 48.4% at the end of basic immunization to 95.2% and 90.5%, and maintained a high level (defined as the positive rate >50%) until 120 days when the positive rates of nCoV NTAb and nCoV S-RBD were still high at 79.5% and 87.2%, respectively. …”

Table_3_Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease.docx by Ruixin Song (15399459)

“…Within 30 days of booster immunization, the positive rates of nCoV NTAb and nCoV S-RBD in patients with CLD rapidly increased from 29.0% and 48.4% at the end of basic immunization to 95.2% and 90.5%, and maintained a high level (defined as the positive rate >50%) until 120 days when the positive rates of nCoV NTAb and nCoV S-RBD were still high at 79.5% and 87.2%, respectively. …”

Table_1_Practical Model to Optimize the Strategy of Adjuvant Postmastectomy Radiotherapy in T1-2N1 Breast Cancer With Modern Systemic Therapy.docx by Fei-Fei Xu (538090)

“…After a median follow-up of 69 months, the 5-year rate of DFS, BCSS, and LRR in the overall cohort was 90.2%, 97.4%, and 3.6%, respectively. …”

Table_2_Durability of immune response after SARS-CoV-2 vaccination in patients with chronic liver disease.docx by Ruixin Song (15399459)

“…Within 30 days of booster immunization, the positive rates of nCoV NTAb and nCoV S-RBD in patients with CLD rapidly increased from 29.0% and 48.4% at the end of basic immunization to 95.2% and 90.5%, and maintained a high level (defined as the positive rate >50%) until 120 days when the positive rates of nCoV NTAb and nCoV S-RBD were still high at 79.5% and 87.2%, respectively. …”

Targeting pan-caspase activation suppresses HIV-1 infection. by Jason Segura (14608801)

“…Primary CD8-depleted PBMC were infected with HIV-1_BAL for 6 days in the presence of 50uM indicated caspase inhibitors and analyzed for the accumulation of p24+/CD62L- populations (<b>A</b>) as well as the level of infection using intracellular p24 staining (<b>B</b>). …”

Image_1_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.TIF by Jiachuan Xiong (748476)

“…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”

Data_Sheet_1_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.docx by Jiachuan Xiong (748476)

“…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”

Image_2_T-Lymphocyte Subsets Alteration, Infection and Renal Outcome in Advanced Chronic Kidney Disease.TIFF by Jiachuan Xiong (748476)

“…The primary outcomes were the major infection and renal outcome.</p><p>Results: A total of 410 CKD patients were enrolled; the average age was 47.25 years. …”

Supplemental Material for Juurakko et al., 2021 by Collin L. Juurakko (10941459)

“…</p><p></p><p></p><p> </p><p>A list of protein accession identifications for all significantly increased and decreased proteins obtained by MS were assembled and used as inputs for STRING (version 11.0) to predict protein-protein interactions (Franceschini <i>et al.…”

Table_8_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_1_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_6_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_10_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.DOCX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Table_2_Meta-analysis of hybrid immunity to mitigate the risk of Omicron variant reinfection.XLSX by Huiling Zheng (49699)

“…The effectiveness of hybrid immunity (incomplete vaccination) in mitigating the risk of reinfection was 37.88% (95% CI, 28.88–46.89%) within 270–364 days, and decreased to 33.23%% (95% CI, 23.80–42.66%) within 365–639 days; whereas, the effectiveness after complete vaccination was 54.36% (95% CI, 50.82–57.90%) within 270–364 days, and the effectiveness of booster vaccination was 73.49% (95% CI, 68.95–78.04%) within 90–119 days.…”

Attention reduces decision uncertainty under high cognitive demand. by Rahul Garg (3064578)

“…Yellow: increased, dark grey: decreased, light grey: unchanged. (M) Bar plots show the percentage of glomeruli exhibiting a change in response for cued vs. un-cued trials. …”